Lisa M Ooms

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Venues

Cancers

International journal of molecular sciences

Proceedings of the National Academy of Sciences of the United States of America

Biochemical Society transactions

University of Melbourne (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Melbourne

Australia

PHD :: Medicine

Publications

Maria Lambouras, Charlotte Roelofs, Melrine Pereira, Emily Gruber, Jessica L Vieusseux, Patrick Lanteri, Cameron N Johnstone, Fenella Muntz, Sandra O'Toole, Lisa M Ooms, Christina A Mitchell, Robin L Anderson, Kara L Britt
Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. International journal of molecular sciences 24 (6) (2023)
Maria Lambouras, Charlotte Roelofs, Melrine Pereira, Emily Gruber, Jessica L Vieusseux, Patrick Lanteri, Cameron N Johnstone, Fenella Muntz, Sandra O'Toole, Lisa M Ooms, Christina A Mitchell, Robin L Anderson, Kara L Britt
Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. International journal of molecular sciences 24 (6) (2023)
Samuel J Rodgers, Christina A Mitchell, Lisa M Ooms
The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer. Biochemical Society transactions (2023)
Maria Lambouras, Charlotte Roelofs, Melrine Pereira, Emily Gruber, Jessica L Vieusseux, Patrick Lanteri, Cameron N Johnstone, Fenella Muntz, Sandra O'Toole, Lisa M Ooms, Christina A Mitchell, Robin L Anderson, Kara L Britt
Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. International journal of molecular sciences 24 (6) (2023)
Samuel J Rodgers, Lisa M Ooms, Christina A Mitchell
The FDA-Approved Drug Pyrvinium Selectively Targets ER + Breast Cancer Cells with High INPP4B Expression. Cancers 15 (1) (2022)
Samuel J Rodgers, Lisa M Ooms, Christina A Mitchell
The FDA-Approved Drug Pyrvinium Selectively Targets ER + Breast Cancer Cells with High INPP4B Expression. Cancers 15 (1) (2022)
Samuel J Rodgers, Lisa M Ooms, Christina A Mitchell
The FDA-Approved Drug Pyrvinium Selectively Targets ER + Breast Cancer Cells with High INPP4B Expression. Cancers 15 (1) (2022)
Samuel J Rodgers, Lisa M Ooms, Viola M J Oorschot, Ralf Bernd Schittenhelm, Elizabeth V Nguyen, Sabryn A Hamila, Natalie Rynkiewicz, Rajendra Gurung, Matthew J Eramo, Absorn Sriratana, Clare G Fedele, Franco Caramia, Sherene Loi, Genevieve Kerr, Helen E Abud, Georg Ramm, Antonella Papa, Andrew M Ellisdon, Roger J Daly, Catriona A Mclean, Christina A Mitchell
INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer. Nature communications 12 (1) (2021)
Samuel J Rodgers, Sabryn A Hamila, Christina A Mitchell, Lisa M Ooms
A late endosome signaling hub that couples PI3Kα and WNT/β-catenin signaling in breast cancer. Molecular & cellular oncology 8 (4) (2021)
Nuthasuda Srijakotre, Heng-Jia Liu, Max Nobis, Joey Man, Hon Yan Kelvin Yip, Antonella Papa, Helen E Abud, Kurt I Anderson, Heidi C E Welch, Tony Tiganis, Paul Timpson, Catriona A Mclean, Lisa M Ooms, Christina A Mitchell
PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis. Proceedings of the National Academy of Sciences of the United States of America 117 (45) (2020)
Guojie Wu, Blake A Mazzitelli, Adam J Quek, Matthew J Veldman, Paul J Conroy, Thomas Tudor Caradoc-Davies, Lisa M Ooms, Kellie L Tuck, Jonathan G Schoenecker, James C Whisstock, Ruby H P Law
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator. Blood advances 3 (5) (2020)

Lisa M Ooms.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lisa M Ooms